Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 3/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.36 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | RECQL | P46063 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.36 |
| ▸ | DAPK1 | P53355 | 2/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22543060 | 0.88 | BCL2 (0.50) | BCL2MCL1AKT1ALOX15MAOA | |
| SCHEMBL21101011 | 0.73 | ALOX15 (0.41) | BCL2MCL1ALOX15MAOATDP1 | |
| SCHEMBL21055664 | 0.73 | MEN1 (0.40) | BCL2MCL1AKT1ALOX15MAOA | |
| SCHEMBL1609319 | 0.73 | ALDH1A1 (0.41) | BCL2MCL1ALOX15TDP1KDM4E | |
| SCHEMBL9672578 | 0.73 | MCL1 (0.50) | BCL2MCL1AKT1ALOX15TDP1 | |
| SCHEMBL8693513 | 0.72 | MAOA (0.53) | BCL2MCL1ALOX15MAOATDP1 | |
| SCHEMBL31634580 | 0.71 | BCL2 (0.50) | BCL2MCL1ALOX15MAOATDP1 | |
| SCHEMBL9166710 | 0.71 | CA12 (0.47) | BCL2MCL1ALOX15MAOATDP1 | |
| SCHEMBL28329948 | 0.70 | ALOX15 (0.46) | BCL2MCL1ALOX15MAOATDP1 | |
| SCHEMBL29181626 | 0.70 | KDM4E (0.50) | BCL2MCL1AKT1ALOX15MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2874664-B1 | COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE-EARTH RADIOISOTOPE COMPLEX | CENTRE EUGENE MARQUIS (FR) | 2019-06-19 | — | — | EP | claimed |
| US-9579409-B2 | Composition for therapeutic use, including an organic lipid phase and a rare-earth radioisotope complex | CENTRE EUGENE MARQUIS (FR) | 2017-02-28 | — | — | US | claimed |
| US-20150202334-A1 | COMPOSITION FOR THERAPEUTIC USE, INCLUDING AN ORGANIC LIPID PHASE AND A RARE-EARTH RADIOISOTOPE COMPLEX | ECOLE NATIONALE SUPERIEURE DE CHIMIE (FR) | 2015-07-23 | — | — | US | claimed |
| EP-1808169-B1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH INC (US) | 2012-05-30 | — | — | EP | claimed |
| JP-4370072-B2 | — | — | 2009-11-25 | — | — | JP | claimed |
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTEOTECH, INC. | 2007-08-16 | — | — | US | claimed |
| EP-1808169-A2 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | Proteotech Inc. (US) | 2007-07-18 | — | — | EP | claimed |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2004-08-05 | — | — | US | claimed |
| JP-2003532634-A | — | — | 2003-11-05 | — | — | JP | claimed |
| EP-0828483-B1 | USE OF TROPOLONE DERIVATIVES AS INHIBITORS OF THE ENZYME INOSITOL MONOPHOSPHATASE | LEPETIT SPA (IT) | 2003-01-29 | — | — | EP | claimed |
| EP-1244435-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND $g(a)-SYNUCLEIN FIBRIL DISEASES | Proteotech Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | PROTAMED, INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001049281-A2 | POLYHYDROXYLATED AROMATIC COMPOUNDS FOR THE TREATMENT OF AMYLOIDOSIS AND α-SYNUCLEIN FIBRIL DISEASES | PROTEOTECH, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| US-5990160-A | Use of tropolone derivatives as inhibitors of the enzyme inositol monophosphatase | GRUPPO LEPETIT, SPA (IT) | 1999-11-23 | — | — | US | claimed |
| EP-0828483-A1 | USE OF TROPOLONE DERIVATIVES AS INHIBITORS OF THE ENZYME INOSITOL MONOPHOSPHATASE | GRUPPO LEPETIT S.p.A. (IT) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037197-A1 | USE OF TROPOLONE DERIVATIVES AS INHIBITORS OF THE ENZYME INOSITOL MONOPHOSPHATASE | GRUPPO LEPETIT S.P.A. (IT) | 1996-11-28 | — | — | WO | claimed |
| EP-4735567-A1 | BIODEGRADABLE CHELATING AGENTS AND METHODS FOR FABRIC CARE | The Procter & Gamble Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735568-A1 | BIODEGRADABLE CHELATING AGENTS AND METHODS FOR FABRIC CARE | The Procter & Gamble Company (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-1996037197-A1 | USE OF TROPOLONE DERIVATIVES AS INHIBITORS OF THE ENZYME INOSITOL MONOPHOSPHATASE | GRUPPO LEPETIT S.P.A. (IT) | 1996-11-28 | — | — | WO | disclosed |
| US-5284866-A | 1H-cycloundeca[1,2-b:5,6-b']biscyclohepta(b)pyrans useful as antitumor agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191330-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | BCL2 241/4885MCL1 4099/4885AKT1 1642/4885 |
| US-20010047032-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | BCL2 244/4885MCL1 4041/4885AKT1 1734/4885 |
| US-20040152760-A1 | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | SNCA, PARK7, HTT | BCL2 244/4885MCL1 4041/4885AKT1 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.